Analyst Reco. Emergent BioSolutions Inc.

Equities

EBS

US29089Q1058

Market Closed - Nyse Other stock markets 04:00:02 2024-04-24 pm EDT			5-day change	1st Jan Change
2.18 ^USD	-4.80%		+14.74%	-9.17%

Apr. 24	Amneal Pharmaceuticals Cleared by FDA to Sell Generic Version of Nasal Spray to Treat Opioid Overdose -- Shares Rise	MT
Mar. 25	Emergent Gets FDA's 'No Action Indicated' Status For Baltimore Bayview Manufacturing Facility	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Benchmark Upgrades Emergent Biosolutions to Buy From Hold, Price Target is $5	Mar. 07	MT
Benchmark Downngrades Emergent Biosolutions to Hold From Buy	23-08-29	MT
Benchmark Upgrades Emergent Biosolutions to Buy From Hold, Price Target is $22	23-04-10	MT
JPMorgan Downgrades Emergent Biosolutions to Underweight From Neutral, Adjusts Price Target to $9 From $23	23-03-17	MT
Chardan Cuts Price Target on Emergent Biosolutions to $55 From $65 on Slower Revenue, Profitability Growth; Keeps Buy Rating	22-11-09	MT
Cowen Trims Emergent Biosolutions Price Target to $29 From $30, Maintains Market Perform Rating	22-09-12	MT
Wells Fargo Adjusts Emergent Biosolutions' Price Target to $38 from $46, Keeps Equalweight Rating	22-05-04	MT
Cantor Fitzgerald Cuts Emergent Biosolutions to Neutral From Overweight, Price Target to $33 From $55	22-05-02	MT
JPMorgan Trims Price Target for Emergent Biosolutions to $57 From $58, Maintains Neutral Rating	22-03-10	MT
Wells Fargo Adjusts Emergent Biosolutions' Price Target to $40 from $37, Keeps Equalweight Rating	22-03-10	MT
Benchmark Upgrades Emergent Biosolutions to Buy from Hold, Sets $77 Price Target	22-01-20	MT
Cantor Fitzgerald Adjusts Price Target on Emergent Biosolutions to $55 From $50, Reiterates Overweight Rating	22-01-20	MT
Chardan Adjusts Price Target on Emergent Biosolutions to $75 From $92, Maintains Buy Rating	21-11-10	MT
Benchmark Capital Downgrades Emergent Biosolutions to Hold From Buy	21-11-08	MT
EMERGENT BIOSOLUTIONS : Argus Research Downgrades Emergent Biosolutions to Hold From Buy	21-05-05	MT
EMERGENT BIOSOLUTIONS : Chardan Adjusts Price Target on Emergent Biosolutions to $92 From $112, Maintains Buy Rating	21-04-30	MT
EMERGENT BIOSOLUTIONS : Benchmark Adjusts Price Target on Emergent Biosolutions to $120 From $150, Maintains Buy Rating	21-04-30	MT
EMERGENT BIOSOLUTIONS : Guggenheim Adjusts Price Target on Emergent Biosolutions to $110 From $130, Maintains Buy Rating	21-04-14	MT
EMERGENT BIOSOLUTIONS : Benchmark Starts Emergent Biosolutions at Buy with $150 Price Target	21-04-07	MT
EMERGENT BIOSOLUTIONS : Chardan Upgrades Emergent BioSolutions to Buy From Neutral, Maintains $112 Price Target	21-02-24	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Emergent BioSolutions Inc.

Equities

EBS

US29089Q1058

Analyst Reco.

Filters